Obiettivo With the increasing volume of genetic sequences, bioinformatics methods, data about variants and mutations, and research publications, clinical interpretation remains a complex and labour-intensive task. As a result, clinical interpretation became the costly piece of genetic testing, limiting scale, keeping turnaround time high, and driving up costs of a test. Moreover, after the geneticist’s work is done, clinicians still remain with partial, insufficient information to base their clinical decisions on.Emedgene have developed an ICT platform for clinical interpretation of genomic data. The platform continuously scans all public resources and databases available, retrieves information from written publications using Natural Language Processing, and intelligently integrates the data into unified ontologies. It is the first artificial intelligence platform, modelled on the behaviour of sophisticated genomic interpreters, to automatically pinpoint the unique disease-causing variants and deliver results with solid evidence and reasoning, providing a clear path to clinical decisions.Within the overall project, Emedgene plan to optimise the platforms interpretations capabilities, demonstrate and validate it in clinical environments, and fully establish the European commercialisation strategy. Campo scientifico scienze naturaliinformatica e scienze dell'informazioneintelligenza artificialescienze mediche e della salutescienze della saluteservizi di assistenza sanitariasanità elettronicascienze naturaliinformatica e scienze dell'informazionescienza dei datielaborazione del linguaggio naturalescienze socialieconomia e commercioeconomia e gestione aziendalemodelli aziendaliscienze naturaliscienze biologichegeneticamutazione Programma(i) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Argomento(i) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Invito a presentare proposte H2020-SMEInst-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2016-2017 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore EMEDGENE TECHNOLOGIES LTD Contribution nette de l'UE € 50 000,00 Indirizzo Derech menachem begin 125 street 6107002 Tel aviv Israele Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Altri finanziamenti € 21 429,00
